论文部分内容阅读
目的探讨髓细胞白血病基因-1(MCL-1)、谷胱甘肽巯基转移酶π(GST-π)、P-糖蛋白(Pgp)在结肠癌发生发展及其在化疗耐药中的意义。方法应用免疫组化的方法检测168例结肠癌及相应癌旁正常组织中MCL-1蛋白的表达水平,分析其表达与结肠癌临床病理参数的关系并探讨其与GST-π、P-gp蛋白的相关性。结果结肠癌中MCL-1、GST-π、P-gp的表达均显著高于癌旁正常组织(P<0.05)。结肠癌中MCL-1的表达与肿瘤分化程度、临床分期、浸润深度及淋巴结转移相关(P<0.05),与性别、年龄及肿瘤大小无关(P>0.05);P-gp与肿瘤浸润深度有关,与肿瘤分化程度、临床分期、淋巴结转移、性别、年龄、肿瘤大小无关(P>0.05);GST-π与分化程度、临床分期、肿瘤浸润深度、淋巴结转移等各临床参数均无关(P>0.05)。MCL-1与P-gp呈正相关(P<0.01),与GST-π无关(P>0.01);P-gp与GST-π呈正相关(P<0.01)。结论 MCL-1的异常表达可能参与了结肠癌的发生发展,并且可能与肿瘤的多药耐药有关。MCL-1可能为临床肿瘤治疗提供新的药物干预靶点,并且可能成为判断结肠癌预后及指导临床化疗的重要因子。
Objective To explore the significance of myeloid leukemia gene-1 (MCL-1), glutathione thiotransferase π (GST-π) and P-glycoprotein (Pgp) in the development of colorectal cancer and its role in chemotherapy resistance. Methods Immunohistochemical method was used to detect the expression of MCL-1 protein in 168 colon cancer tissues and corresponding normal tissues. The relationship between the expression of the MCL-1 protein and the clinicopathological parameters of colon cancer was analyzed, and its relationship with GST-π, P-gp protein was discussed. The relevance. Results The expressions of MCL-1, GST-π and P-gp in colon cancer were significantly higher than those in adjacent normal tissues (P<0.05). The expression of MCL-1 in colon cancer was related to tumor differentiation, clinical stage, depth of invasion, and lymph node metastasis (P<0.05), but not to gender, age, and tumor size (P>0.05). P-gp was associated with depth of tumor invasion. There was no relationship between tumor differentiation, clinical stage, lymph node metastasis, gender, age, and tumor size (P>0.05). GST-π had nothing to do with clinical parameters such as differentiation degree, clinical stage, depth of tumor invasion, and lymph node metastasis (P> 0.05). There was a positive correlation between MCL-1 and P-gp (P<0.01) and no correlation with GST-π (P>0.01). There was a positive correlation between P-gp and GST-π (P<0.01). Conclusion The abnormal expression of MCL-1 may be involved in the occurrence and development of colon cancer, and may be related to the multidrug resistance of tumors. MCL-1 may provide a new drug intervention target for clinical tumor treatment, and may become an important factor in judging the prognosis of colon cancer and guiding clinical chemotherapy.